{"id":"NCT02296424","sponsor":"Novartis Pharmaceuticals","briefTitle":"ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab","officialTitle":"β-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-17","primaryCompletion":"2016-10-14","completion":"2017-09-25","firstPosted":"2014-11-20","resultsPosted":"2019-07-09","lastUpdate":"2019-07-09"},"enrollment":182,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Systemic Juvenile Idiopathic Arthritis (SJIA)"],"interventions":[{"type":"DRUG","name":"ACZ885 150 mg (Canakinumab)","otherNames":["ACZ885 150 mg"]}],"arms":[{"label":"Canakinumab Dose Reduction","type":"EXPERIMENTAL"},{"label":"Canakinumab Dose Interval Prolongation","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.","primaryOutcome":{"measure":"Number of Participants in Clinical Remission on Canakinumab Who Are Able to Remain at an Initial Reduced Canakinumab Dose or Prolonged Canakinumab Dose Interval.","timeFrame":"baseline to 24 weeks","effectByArm":[{"arm":"Canakinumab Dose Reduction","deltaMin":27,"sd":null},{"arm":"Canakinumab Dose Interval Prolongation","deltaMin":31,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":3},"locations":{"siteCount":50,"countries":["United States","Austria","Belgium","Brazil","Canada","France","Germany","Hungary","Israel","Italy","Netherlands","Poland","Russia","Spain","Sweden","Turkey (Türkiye)"]},"refs":{"pmids":["32783351"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":166},"commonTop":["Pyrexia","Nasopharyngitis","Arthralgia","Headache","Upper respiratory tract infection"]}}